- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03878368
Broccoli In Osteoarthritis (BRIO)
A Dietary Intervention Trial to Examine the Effect of Broccoli Bioactives (Specifically Sulforaphane) on Osteoarthritis (OA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is the first clinical trial to test the benefits of eating broccoli on pain and physical function in knee osteoarthritis (OA).
Many fruits and vegetables in the normal human diet contain substances that may improve human health or disease. There is increasingly strong laboratory data that indicate that exposure to these substances at the levels found in the diet influence the way in which osteoarthritis develops. Sulforaphane (SFN) is a naturally occurring substance found in vegetables such as broccoli and is known to have helpful effects on cartilage cells. Sulforaphane derived from broccoli, has a potential role in limiting pain and cartilage destruction in OA.
The investigators have shown that:
- SFN can stop inflammation in mice with OA
- SFN blocks the production of the enzymes which break down cartilage in OA, both in cell cultures and in pieces of cartilage
- SFN enters the joint in participants provided with a high broccoli diet ahead of a knee replacement and alters the types of proteins present in the joint fluid
The investigators aim to discover for the first time in man, whether a broccoli-rich diet will improve pain and physical function in participants with knee osteoarthritis. The study will provide the much-needed preliminary data that will allow the investigators to design a clinical trial to prove that broccoli can be recommended as a helpful food for people with OA.
The trial will compare broccoli soup (rich in SFN) with a soup, which does not contain broccoli (control), but looks and tastes the same. Sixty-four participants with moderate osteoarthritis will either have the broccoli or the control soup, chosen at random. The participants will eat the soup once-a-day, for 4 days-a-week for 3 months. The investigators will measure pain and physical function at the start of the trial, at 6 weeks and at 12 weeks and look at the changes in these. The investigators will also take blood samples and collect urine to measure SFN levels.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Norfolk
-
Norwich, Norfolk, United Kingdom, NR4 7UY
- Norfolk & Norwich University Hospital
-
-
West Yorkshire
-
Leeds, West Yorkshire, United Kingdom, LS7 4SA
- Chapel Allerton Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Current knee pain, defined as pain in either knee, in the (one) month before Visit 1, for which the patient gives a severity score of at least 4 on a 0-10 numeric rating scale (NRS).
- The target knee should fulfil the criteria of the American College of Rheumatology (ACR) for knee osteoarthritis defined as knee pain for most days of the prior month and at least one of the following three factors: age over 50 years; morning stiffness of less than 30 minutes; knee crepitus on motion.
- Kellgren Lawrence grade 2-3
- Stable analgesic usage (if using) for 4 weeks prior to trial entry and throughout the trial duration
- Able to adhere to the study visit schedule and other protocol requirements (willing to consume soup intervention).
- Willing to provide 24 hour urine collection samples (x3)
- Capable of giving informed consent and the consent must be obtained prior to any screening procedures.
Exclusion Criteria:
- The presence of any inflammatory arthritis (e.g. gout, reactive arthritis, rheumatoid arthritis, psoriatic arthritis, seronegative spondylarthropathy) or fibromyalgia or metabolic bone disease.
- Any clinically significant uncontrolled concurrent illness, which, in the opinion of the Investigator, would impair ability to give informed consent or take part in or complete this clinical study.
- Known or suspected intolerance or hypersensitivity to the investigational product (broccoli) or standardised meal (see section 9.2), closely related compounds, or any of the stated ingredients.
- Use of an investigational product within 30 days prior to 'run in' period or active enrolment in another drug or vaccine clinical study.
- Significant knee injury or any knee surgery within the 6 months preceding enrolment in the study.
- A history of partial or complete joint replacement surgery in the signal knee at any time, listed for knee surgery, or anticipating knee surgery during the study period.
- Poor tolerability of venepuncture or lack of adequate venous access for required blood sampling during the study period
- Nutritional deficiency
- Use of anticoagulant medication (see notes for inclusion exclusion criteria)
- Use of intra-articular hyaluronic acid in the signal knee within the 3 months preceding enrolment in the study.
- Use of intra-articular, intra-muscular or oral corticosteroids in the 2 months preceding enrolment.
- Commencement of non-pharmacological interventions within two months preceding enrolment.
- Persons less than 50 years
- Pregnant/lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
32 participants with moderate osteoarthritis will eat soup with the active ingredient once-a-day for 4 days-a-week for 3 months.
|
Intervention soup with dietary sulforaphane
|
Active Comparator: Control
32 participants with moderate osteoarthritis will eat soup without the active ingredient once-a-day for 4 days-a-week for 3 months.
|
Control soup without dietary sulforaphane
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
WOMAC (Western Ontario and McMaster Universities Arthritis Index)
Time Frame: Baseline and 12 weeks.
|
Change in the WOMAC (Western Ontario and McMaster Universities Arthritis Index) pain subscale.
|
Baseline and 12 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
WOMAC (Western Ontario and McMaster Universities Arthritis Index): Pain
Time Frame: 6 weeks
|
Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing upright
|
6 weeks
|
WOMAC (Western Ontario and McMaster Universities Arthritis Index): Physical Function
Time Frame: 6 & 12 weeks
|
Physical Function (17 items): using stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy domestic duties, light domestic duties
|
6 & 12 weeks
|
WOMAC (Western Ontario and McMaster Universities Arthritis Index): Stiffness
Time Frame: 6 & 12 weeks
|
Stiffness (2 items): after first waking and later in the day
|
6 & 12 weeks
|
11 Point Pain Numerical Rating Scale (NRS): Average overall knee pain severity in the index knee over the past 1 week
Time Frame: 6&12 weeks
|
Minimum score '0' to maximum score '10' Lower numerical value is the better outcome
|
6&12 weeks
|
11 Point Pain Numerical Rating Scale (NRS): Worst knee pain severity in the index knee over the past 1 week
Time Frame: 6&12 weeks
|
Minimum score '0' to maximum score '10' Lower numerical value is the better outcome
|
6&12 weeks
|
11 Point Pain Numerical Rating Scale (NRS): Global disease activity over the past 1 week
Time Frame: 6&12 weeks
|
Minimum score '0' to maximum score '10' Lower numerical value is the better outcome
|
6&12 weeks
|
11 point pain Numerical Rating Scale (NRS): Satisfaction with index knee function over the past 1 week
Time Frame: 6&12 weeks
|
Minimum score '0' to maximum score '10' Lower numerical value is the better outcome
|
6&12 weeks
|
11 point pain Numerical Rating Scale (NRS): Average pain in other joints over the past 1 week
Time Frame: 6&12 weeks
|
Minimum score '0' to maximum score '10' Lower numerical value is the better outcome
|
6&12 weeks
|
Pain in other joints
Time Frame: 6&12 weeks
|
Joint manikin
|
6&12 weeks
|
Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)
Time Frame: 6&12 weeks
|
Self-Assessment
|
6&12 weeks
|
Rescue analgesics/NSAIDs
Time Frame: 6&12 weeks
|
Use of rescue analgesics/NSAIDs
|
6&12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Alexander MacGregor, PhD, University of East Anglia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BRIO Protocol V4.0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Mayo ClinicCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Sword Health, SAHospital da PreladaCompletedEfficacy of a Digital Biofeedback System for Home-based Rehabilitation After Total Joint ReplacementKnee Osteoarthritis | Hip OsteoarthritisPortugal
-
The Hawkins FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
Massachusetts General HospitalNewton-Wellesley HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Sulforaphane
-
Johns Hopkins UniversityTemple University; State University of New York at BuffaloCompleted
-
University of OxfordQuadram Institute BioscienceRecruitingObesity | Metabolic Syndrome | Non-Alcoholic Fatty Liver DiseaseUnited Kingdom
-
Second Affiliated Hospital, School of Medicine,...UnknownAlzheimer DiseaseChina
-
Andrew ZimmermanJohns Hopkins UniversityCompleted
-
John KirkwoodCompletedMelanoma | Atypical NeviUnited States
-
Central South UniversityStanley Medical Research InstituteCompleted
-
Xiangya Hospital of Central South UniversityUnknownFrontal Lobe Dysfunction
-
Johns Hopkins UniversityRecruitingSkin AgingUnited States
-
Karolinska InstitutetLantmännenCompletedDiabetes Mellitus, Type 2 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BSweden
-
Anders Rosengren, MD PhDCompletedDiabetes Mellitus, Non-Insulin-Dependent